세계의 동물용 mRNA 백신 : 시장 점유율과 순위, 전체 판매량 및 수요 예측(2025-2031년)

The global market for mRNA Vaccines for Animals was estimated to be worth US$ 81.02 million in 2024 and is forecast to a readjusted size of US$ 2513 million by 2031 with a CAGR of 61.1% during the forecast period 2025-2031.

mRNA vaccines for animals are a type of veterinary vaccine that use messenger RNA (mRNA) technology to stimulate an immune response against specific pathogens in livestock, pets, and other animals. These vaccines work by delivering synthetic mRNA encoding viral or bacterial antigens into the animal's cells, prompting the immune system to recognize and fight the targeted disease. Compared to traditional vaccines, mRNA vaccines offer faster development timelines, improved efficacy, and the ability to rapidly adapt to emerging animal diseases. They are being explored for various applications, including livestock diseases (such as foot-and-mouth disease), zoonotic infections, and companion animal health.

Market Development Opportunities & Main Driving Factors

mRNA vaccines for animals, as a new generation of biological products, are reshaping the global veterinary vaccine landscape with their rapid development, high specificity, and scalability. According to annual reports from animal health companies and brokerage research, the demand for epidemic prevention in the livestock industry continues to rise, particularly against transboundary infectious diseases and major animal epidemics, which accelerates investment in novel vaccines. The proven success of mRNA technology in human COVID-19 vaccines validates its potential in veterinary applications. Coupled with strong policy support for food safety, livestock modernization, and public health, the market expansion potential for animal mRNA vaccines is significant.

Market Challenges, Risks, & Restraints

Despite promising prospects, animal mRNA vaccines face multiple challenges. Their storage, transportation, and mass production require stringent cold chain and advanced equipment, leading to higher costs compared to traditional vaccines. Regulatory frameworks remain immature, with varying standards for registration and safety validation across regions, adding uncertainty to commercialization. Additionally, the industry is dominated by multinational animal health giants with strong technological and financial advantages, creating barriers for smaller firms facing fierce competition and potential technological hurdles.

Downstream Demand Trends

As livestock farming becomes increasingly large-scale and intensive, and as consumer awareness of food safety and animal health grows, demand for safe and effective novel vaccines continues to rise. In particular, poultry, swine, and companion animal sectors exhibit strong demand for rapid-response vaccines against emerging diseases. Growing government investment in animal disease prevention and farmers' need to reduce losses and improve efficiency will further drive adoption. In the long term, animal mRNA vaccines are poised to become a critical technology supporting livestock stability and food supply security.

This report aims to provide a comprehensive presentation of the global market for mRNA Vaccines for Animals, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of mRNA Vaccines for Animals by region & country, by Type, and by Application.

The mRNA Vaccines for Animals market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding mRNA Vaccines for Animals.

Market Segmentation

By Company

• Ceva Animal Health
• Merck Animal Health
• Areterna
• Bayer
• BioNTech
• Genvax Technologies
• BioVenic
• Moderna
• Ruipu Biotechnology
• Jinyu Bio-technology
• Shanghai Shen Lian Biomedical
• Suzhou Kerui Meide Biomedical Technology
• Shanghai Rnacure Biopharma

Segment by Type

• Non-replicating mRNA vaccines
• Self-replicating mRNA vaccines

Segment by Application

• Pigs
• Poultry
• Companion Animals
• Ruminants

By Region

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • South Korea
  • Southeast Asia
  • India
  • Australia
  • Rest of Asia-Pacific
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Netherlands
  • Nordic Countries
  • Rest of Europe
• Latin America
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa
  • Turkey
  • Saudi Arabia
  • UAE
  • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of mRNA Vaccines for Animals company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of mRNA Vaccines for Animals in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of mRNA Vaccines for Animals in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

• 1.1 mRNA Vaccines for Animals Product Introduction
• 1.2 Global mRNA Vaccines for Animals Market Size Forecast (2020-2031)
• 1.3 mRNA Vaccines for Animals Market Trends & Drivers
  • 1.3.1 mRNA Vaccines for Animals Industry Trends
  • 1.3.2 mRNA Vaccines for Animals Market Drivers & Opportunity
  • 1.3.3 mRNA Vaccines for Animals Market Challenges
  • 1.3.4 mRNA Vaccines for Animals Market Restraints
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Competitive Analysis by Company

• 2.1 Global mRNA Vaccines for Animals Players Revenue Ranking (2024)
• 2.2 Global mRNA Vaccines for Animals Revenue by Company (2020-2025)
• 2.3 Key Companies mRNA Vaccines for Animals Manufacturing Base Distribution and Headquarters
• 2.4 Key Companies mRNA Vaccines for Animals Product Offered
• 2.5 Key Companies Time to Begin Mass Production of mRNA Vaccines for Animals
• 2.6 mRNA Vaccines for Animals Market Competitive Analysis
  • 2.6.1 mRNA Vaccines for Animals Market Concentration Rate (2020-2025)
  • 2.6.2 Global 5 and 10 Largest Companies by mRNA Vaccines for Animals Revenue in 2024
  • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in mRNA Vaccines for Animals as of 2024)
• 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

• 3.1 Introduction by Type
  • 3.1.1 Non-replicating mRNA vaccines
  • 3.1.2 Self-replicating mRNA vaccines
• 3.2 Global mRNA Vaccines for Animals Sales Value by Type
  • 3.2.1 Global mRNA Vaccines for Animals Sales Value by Type (2020 VS 2024 VS 2031)
  • 3.2.2 Global mRNA Vaccines for Animals Sales Value, by Type (2020-2031)
  • 3.2.3 Global mRNA Vaccines for Animals Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

• 4.1 Introduction by Application
  • 4.1.1 Pigs
  • 4.1.2 Poultry
  • 4.1.3 Companion Animals
  • 4.1.4 Ruminants
• 4.2 Global mRNA Vaccines for Animals Sales Value by Application
  • 4.2.1 Global mRNA Vaccines for Animals Sales Value by Application (2020 VS 2024 VS 2031)
  • 4.2.2 Global mRNA Vaccines for Animals Sales Value, by Application (2020-2031)
  • 4.2.3 Global mRNA Vaccines for Animals Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

• 5.1 Global mRNA Vaccines for Animals Sales Value by Region
  • 5.1.1 Global mRNA Vaccines for Animals Sales Value by Region: 2020 VS 2024 VS 2031
  • 5.1.2 Global mRNA Vaccines for Animals Sales Value by Region (2020-2025)
  • 5.1.3 Global mRNA Vaccines for Animals Sales Value by Region (2026-2031)
  • 5.1.4 Global mRNA Vaccines for Animals Sales Value by Region (%), (2020-2031)
• 5.2 North America
  • 5.2.1 North America mRNA Vaccines for Animals Sales Value, 2020-2031
  • 5.2.2 North America mRNA Vaccines for Animals Sales Value by Country (%), 2024 VS 2031
• 5.3 Europe
  • 5.3.1 Europe mRNA Vaccines for Animals Sales Value, 2020-2031
  • 5.3.2 Europe mRNA Vaccines for Animals Sales Value by Country (%), 2024 VS 2031
• 5.4 Asia Pacific
  • 5.4.1 Asia Pacific mRNA Vaccines for Animals Sales Value, 2020-2031
  • 5.4.2 Asia Pacific mRNA Vaccines for Animals Sales Value by Region (%), 2024 VS 2031
• 5.5 South America
  • 5.5.1 South America mRNA Vaccines for Animals Sales Value, 2020-2031
  • 5.5.2 South America mRNA Vaccines for Animals Sales Value by Country (%), 2024 VS 2031
• 5.6 Middle East & Africa
  • 5.6.1 Middle East & Africa mRNA Vaccines for Animals Sales Value, 2020-2031
  • 5.6.2 Middle East & Africa mRNA Vaccines for Animals Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

• 6.1 Key Countries/Regions mRNA Vaccines for Animals Sales Value Growth Trends, 2020 VS 2024 VS 2031
• 6.2 Key Countries/Regions mRNA Vaccines for Animals Sales Value, 2020-2031
• 6.3 United States
  • 6.3.1 United States mRNA Vaccines for Animals Sales Value, 2020-2031
  • 6.3.2 United States mRNA Vaccines for Animals Sales Value by Type (%), 2024 VS 2031
  • 6.3.3 United States mRNA Vaccines for Animals Sales Value by Application, 2024 VS 2031
• 6.4 Europe
  • 6.4.1 Europe mRNA Vaccines for Animals Sales Value, 2020-2031
  • 6.4.2 Europe mRNA Vaccines for Animals Sales Value by Type (%), 2024 VS 2031
  • 6.4.3 Europe mRNA Vaccines for Animals Sales Value by Application, 2024 VS 2031
• 6.5 China
  • 6.5.1 China mRNA Vaccines for Animals Sales Value, 2020-2031
  • 6.5.2 China mRNA Vaccines for Animals Sales Value by Type (%), 2024 VS 2031
  • 6.5.3 China mRNA Vaccines for Animals Sales Value by Application, 2024 VS 2031
• 6.6 Japan
  • 6.6.1 Japan mRNA Vaccines for Animals Sales Value, 2020-2031
  • 6.6.2 Japan mRNA Vaccines for Animals Sales Value by Type (%), 2024 VS 2031
  • 6.6.3 Japan mRNA Vaccines for Animals Sales Value by Application, 2024 VS 2031
• 6.7 South Korea
  • 6.7.1 South Korea mRNA Vaccines for Animals Sales Value, 2020-2031
  • 6.7.2 South Korea mRNA Vaccines for Animals Sales Value by Type (%), 2024 VS 2031
  • 6.7.3 South Korea mRNA Vaccines for Animals Sales Value by Application, 2024 VS 2031
• 6.8 Southeast Asia
  • 6.8.1 Southeast Asia mRNA Vaccines for Animals Sales Value, 2020-2031
  • 6.8.2 Southeast Asia mRNA Vaccines for Animals Sales Value by Type (%), 2024 VS 2031
  • 6.8.3 Southeast Asia mRNA Vaccines for Animals Sales Value by Application, 2024 VS 2031
• 6.9 India
  • 6.9.1 India mRNA Vaccines for Animals Sales Value, 2020-2031
  • 6.9.2 India mRNA Vaccines for Animals Sales Value by Type (%), 2024 VS 2031
  • 6.9.3 India mRNA Vaccines for Animals Sales Value by Application, 2024 VS 2031

7 Company Profiles

• 7.1 Ceva Animal Health
  • 7.1.1 Ceva Animal Health Profile
  • 7.1.2 Ceva Animal Health Main Business
  • 7.1.3 Ceva Animal Health mRNA Vaccines for Animals Products, Services and Solutions
  • 7.1.4 Ceva Animal Health mRNA Vaccines for Animals Revenue (US$ Million) & (2020-2025)
  • 7.1.5 Ceva Animal Health Recent Developments
• 7.2 Merck Animal Health
  • 7.2.1 Merck Animal Health Profile
  • 7.2.2 Merck Animal Health Main Business
  • 7.2.3 Merck Animal Health mRNA Vaccines for Animals Products, Services and Solutions
  • 7.2.4 Merck Animal Health mRNA Vaccines for Animals Revenue (US$ Million) & (2020-2025)
  • 7.2.5 Merck Animal Health Recent Developments
• 7.3 Areterna
  • 7.3.1 Areterna Profile
  • 7.3.2 Areterna Main Business
  • 7.3.3 Areterna mRNA Vaccines for Animals Products, Services and Solutions
  • 7.3.4 Areterna mRNA Vaccines for Animals Revenue (US$ Million) & (2020-2025)
  • 7.3.5 Areterna Recent Developments
• 7.4 Bayer
  • 7.4.1 Bayer Profile
  • 7.4.2 Bayer Main Business
  • 7.4.3 Bayer mRNA Vaccines for Animals Products, Services and Solutions
  • 7.4.4 Bayer mRNA Vaccines for Animals Revenue (US$ Million) & (2020-2025)
  • 7.4.5 Bayer Recent Developments
• 7.5 BioNTech
  • 7.5.1 BioNTech Profile
  • 7.5.2 BioNTech Main Business
  • 7.5.3 BioNTech mRNA Vaccines for Animals Products, Services and Solutions
  • 7.5.4 BioNTech mRNA Vaccines for Animals Revenue (US$ Million) & (2020-2025)
  • 7.5.5 BioNTech Recent Developments
• 7.6 Genvax Technologies
  • 7.6.1 Genvax Technologies Profile
  • 7.6.2 Genvax Technologies Main Business
  • 7.6.3 Genvax Technologies mRNA Vaccines for Animals Products, Services and Solutions
  • 7.6.4 Genvax Technologies mRNA Vaccines for Animals Revenue (US$ Million) & (2020-2025)
  • 7.6.5 Genvax Technologies Recent Developments
• 7.7 BioVenic
  • 7.7.1 BioVenic Profile
  • 7.7.2 BioVenic Main Business
  • 7.7.3 BioVenic mRNA Vaccines for Animals Products, Services and Solutions
  • 7.7.4 BioVenic mRNA Vaccines for Animals Revenue (US$ Million) & (2020-2025)
  • 7.7.5 BioVenic Recent Developments
• 7.8 Moderna
  • 7.8.1 Moderna Profile
  • 7.8.2 Moderna Main Business
  • 7.8.3 Moderna mRNA Vaccines for Animals Products, Services and Solutions
  • 7.8.4 Moderna mRNA Vaccines for Animals Revenue (US$ Million) & (2020-2025)
  • 7.8.5 Moderna Recent Developments
• 7.9 Ruipu Biotechnology
  • 7.9.1 Ruipu Biotechnology Profile
  • 7.9.2 Ruipu Biotechnology Main Business
  • 7.9.3 Ruipu Biotechnology mRNA Vaccines for Animals Products, Services and Solutions
  • 7.9.4 Ruipu Biotechnology mRNA Vaccines for Animals Revenue (US$ Million) & (2020-2025)
  • 7.9.5 Ruipu Biotechnology Recent Developments
• 7.10 Jinyu Bio-technology
  • 7.10.1 Jinyu Bio-technology Profile
  • 7.10.2 Jinyu Bio-technology Main Business
  • 7.10.3 Jinyu Bio-technology mRNA Vaccines for Animals Products, Services and Solutions
  • 7.10.4 Jinyu Bio-technology mRNA Vaccines for Animals Revenue (US$ Million) & (2020-2025)
  • 7.10.5 Jinyu Bio-technology Recent Developments
• 7.11 Shanghai Shen Lian Biomedical
  • 7.11.1 Shanghai Shen Lian Biomedical Profile
  • 7.11.2 Shanghai Shen Lian Biomedical Main Business
  • 7.11.3 Shanghai Shen Lian Biomedical mRNA Vaccines for Animals Products, Services and Solutions
  • 7.11.4 Shanghai Shen Lian Biomedical mRNA Vaccines for Animals Revenue (US$ Million) & (2020-2025)
  • 7.11.5 Shanghai Shen Lian Biomedical Recent Developments
• 7.12 Suzhou Kerui Meide Biomedical Technology
  • 7.12.1 Suzhou Kerui Meide Biomedical Technology Profile
  • 7.12.2 Suzhou Kerui Meide Biomedical Technology Main Business
  • 7.12.3 Suzhou Kerui Meide Biomedical Technology mRNA Vaccines for Animals Products, Services and Solutions
  • 7.12.4 Suzhou Kerui Meide Biomedical Technology mRNA Vaccines for Animals Revenue (US$ Million) & (2020-2025)
  • 7.12.5 Suzhou Kerui Meide Biomedical Technology Recent Developments
• 7.13 Shanghai Rnacure Biopharma
  • 7.13.1 Shanghai Rnacure Biopharma Profile
  • 7.13.2 Shanghai Rnacure Biopharma Main Business
  • 7.13.3 Shanghai Rnacure Biopharma mRNA Vaccines for Animals Products, Services and Solutions
  • 7.13.4 Shanghai Rnacure Biopharma mRNA Vaccines for Animals Revenue (US$ Million) & (2020-2025)
  • 7.13.5 Shanghai Rnacure Biopharma Recent Developments

8 Industry Chain Analysis

• 8.1 mRNA Vaccines for Animals Industrial Chain
• 8.2 mRNA Vaccines for Animals Upstream Analysis
  • 8.2.1 Key Raw Materials
  • 8.2.2 Raw Materials Key Suppliers
  • 8.2.3 Manufacturing Cost Structure
• 8.3 Midstream Analysis
• 8.4 Downstream Analysis (Customers Analysis)
• 8.5 Sales Model and Sales Channels
  • 8.5.1 mRNA Vaccines for Animals Sales Model
  • 8.5.2 Sales Channel
  • 8.5.3 mRNA Vaccines for Animals Distributors

9 Research Findings and Conclusion

10 Appendix

• 10.1 Research Methodology
  • 10.1.1 Methodology/Research Approach
    • 10.1.1.1 Research Programs/Design
    • 10.1.1.2 Market Size Estimation
    • 10.1.1.3 Market Breakdown and Data Triangulation
  • 10.1.2 Data Source
    • 10.1.2.1 Secondary Sources
    • 10.1.2.2 Primary Sources
• 10.2 Author Details
• 10.3 Disclaimer